Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the major reasons for seeking human monoclonal antibodies has been to eliminate immunogenicity seen with rodent antibodies. Thus far, there has yet been no approach which absolutely abolishes that risk for cell-binding antibodies. In this short article, I draw attention to classical work which shows that monomeric immunoglobulins are intrinsically tolerogenic if they can be prevented from creating aggregates or immune complexes. Based on these classical studies two approaches for active tolerization to therapeutic antibodies are described.

Original publication

DOI

10.1007/978-1-62703-586-6_1

Type

Journal article

Journal

Methods Mol Biol

Publication Date

2014

Volume

1060

Pages

1 - 8

Keywords

Animals, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Humans, Immune Tolerance